Expert Interview
Discussing Roivant subsidiary Dermavant Sciences’ recent Phase 3 data of tapinarof in plaque psoriasis ahead of the Q2 PDUFA
Ticker(s): ROIVA dermatologist with knowledge about Roivant’s Tapinarof Cream for Adults with Plaque Psoriasis.
Please tell us about your clinical experience. How many Plaque Psoriasis patients do you see on a yearly basis? What’s the standard of care in this space?
What treatment gets best results in percentage body surface area (%BSA) affected and in Psoriasis Area and Severity Index (PASI), and Dermatology Life Quality Index (DLQI)?
Added By: slingshot_insightsWhat is the irritation level of your patients after standard of care treatment? How does Roivant’s irritation score of 0 across 40 weeks compare?
Could you please comment on tapinarof’s reported mean PASI score, PASI75, PASI90, %BSA Affected, DLQI, and local tolerability scores?
How likely are you to prescribe tapinarof cream in the eventuality of an approval? What do you feel would be its pros and cons compared to standard of care?
Added By: slingshot_insightsAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
